Targeted Genetics Expands AAV Vector Patent Portfolio
SEATTLE, May 17 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation
(NASDAQ:TGEN) today announced the issuance of an additional patent related to
its adeno-associated virus (AAV) vector technology. U.S. patent #6,893,865,
titled "Methods, Compositions and Cells for Encapsidating Recombinant Vectors
in AAV Particles," expands Targeted Genetics' AAV vector systems used for gene
delivery. Targeted Genetics' leading gene delivery vehicle, AAV, is used to
deliver a gene of interest into cells of the patient to impact disease. The
Company uses AAV technology for its current development programs targeting AIDS
prophylaxis, inflammatory arthritis, hyperlipidemia, congestive heart failure,
and Huntington's disease. AAV can be used in general to deliver a broad range
of nucleic acids as disease therapeutics or prophylactics.
The patent describes AAV vectors that utilize a small, human DNA sequence, P1.
AAV vectors require a recognition signal in order to promote the formation of
AAV viral particles containing the therapeutic gene of interest. In this
patented vector system, the human P1 segment efficiently provides that
function.
"Targeted Genetics' latest patent expands the Company's AAV vector technology,"
said Barrie J. Carter, Ph.D., chief scientific officer of Targeted Genetics.
"This patent complements our existing patent that issued for the use of P1 in
our manufacturing processes. The utilization of P1 provides alternative AAV
design strategies that enhance and protect our competitive position. This
expansion of Targeted Genetics' patent portfolio further solidifies our
leadership position in the field of AAV vector technology and AAV
manufacturing." About Targeted Genetics Targeted Genetics Corporation develops molecular medicines for the prevention
and treatment of acquired and inherited diseases. The Company has clinical
product development programs targeting AIDS prophylaxis and inflammatory
arthritis. The Company also has a promising pipeline of preclinical product
development programs focused on hyperlipidemia, congestive heart failure, and
Huntington's disease. For more information about Targeted Genetics, visit its
website at http://www.targetedgenetics.com/.
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This release contains forward-looking statements regarding our intellectual
property, research programs and clinical trials, our product development and
our potential development platforms including AAV vectors and other statements
about our plans, objectives, intentions and expectations. In particular, the
statements regarding the Company's pipeline and potential application of this
patent to any future product candidates are forward-looking statements. These
statements, involve current expectations, forecasts of future events and other
statements that are not historical facts. Inaccurate assumptions and known and
unknown risks and uncertainties can affect the accuracy of forward-looking
statements. Factors that could affect our actual results include, but are not
limited to, results of animal research are not necessarily indicative of
results in humans, the timing, nature and results of our research, potential
development of alternative technologies or more effective products by
competitors, our ability to obtain and maintain regulatory or institutional
approvals, our ability to obtain, maintain and protect our intellectual
property and our ability to raise capital when needed, as well as other risk
factors described in the section entitled "Factors Affecting Our Operating
Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q
for the period ended March 31, 2005. You should not rely unduly on these
forward-looking statements, which apply only as of the date of this release. We
undertake no duty to publicly announce or report revisions to these statements
as new information becomes available that may change our expectations.
Contact: Stacie D. Byars, Director, Communications of Targeted Genetics
Corporation, +1-206-521-7392. DATASOURCE: Targeted Genetics Corporation CONTACT: Stacie D. Byars, Director, Communications of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.targetedgenetics.com/
|